Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa.
Wilma A StolkLuc E CoffengFatorma K BolayObiora A EneanyaPeter U FischerT Déirdre HollingsworthBenjamin G KoudouAboulaye MéitéEdwin MichaelJoaquin M PradaRocio M Caja RiveraSwarnali SharmaPanayiota TouloupouGary J WeilSake J de VlasPublished in: PLoS neglected tropical diseases (2022)
For African areas with moderate to high pre-treatment Mf prevalence that have had 6 or more rounds of annual ivermectin/albendazole MDA with adequate coverage, we recommend to adopt a CFA threshold prevalence of 10% in adults (15+) for stopping MDA. This could be combined with Mf testing of CFA positives to ensure absence of a significant Mf reservoir for transmission.